| Literature DB >> 33280085 |
Beatriz de la Cruz-Benito1, María I Rivas-Pollmar1, María T Álvarez Román1, Roberto Trelles-Martínez1, Monica Martín-Salces1, Paula Lázaro-Del Campo1, Andrés Ramírez-López1, Sara García-Barcenilla1, Tamara Cebanu1, Paula Acuña-Butta1, Elena Monzón-Manzano1, Elena González-Zorrilla1, Victor Jiménez-Yuste1,2, Nora V Butta1.
Abstract
Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID-19) in patients with immune thrombocytopenia (ITP), a retrospective single-centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS-CoV-2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID-19 could explain this paradoxical effect, although further studies are needed.Entities:
Keywords: COVID-19; SARS-CoV-2; immune thrombocytopenia; lymphopenia; thrombocytosis
Mesh：
Year: 2020 PMID： 33280085 DOI： 10.1111/bjh.17077
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998